Historical Valuation
Unicycive Therapeutics Inc (UNCY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.12 is considered Undervalued compared with the five-year average of -0.46. The fair price of Unicycive Therapeutics Inc (UNCY) is between 15.56 to 33.28 according to relative valuation methord. Compared to the current price of 6.18 USD , Unicycive Therapeutics Inc is Undervalued By 60.27%.
Relative Value
Fair Zone
15.56-33.28
Current Price：6.18
60.27%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Unicycive Therapeutics Inc (UNCY) has a current Price-to-Book (P/B) ratio of 3.23. Compared to its 3-year average P/B ratio of -1.79 , the current P/B ratio is approximately -280.18% higher. Relative to its 5-year average P/B ratio of -1.13, the current P/B ratio is about -385.05% higher. Unicycive Therapeutics Inc (UNCY) has a Forward Free Cash Flow (FCF) yield of approximately -23.97%. Compared to its 3-year average FCF yield of -67.42%, the current FCF yield is approximately -64.45% lower. Relative to its 5-year average FCF yield of -63.50% , the current FCF yield is about -62.25% lower.
P/B
Median3y
-1.79
Median5y
-1.13
FCF Yield
Median3y
-67.42
Median5y
-63.50
Competitors Valuation Multiple
AI Analysis for UNCY
The average P/S ratio for UNCY competitors is 11.71, providing a benchmark for relative valuation. Unicycive Therapeutics Inc Corp (UNCY.O) exhibits a P/S ratio of 1.12, which is -90.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for UNCY
1Y
3Y
5Y
Market capitalization of UNCY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of UNCY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is UNCY currently overvalued or undervalued?
Unicycive Therapeutics Inc (UNCY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.12 is considered Undervalued compared with the five-year average of -0.46. The fair price of Unicycive Therapeutics Inc (UNCY) is between 15.56 to 33.28 according to relative valuation methord. Compared to the current price of 6.18 USD , Unicycive Therapeutics Inc is Undervalued By 60.27% .
What is Unicycive Therapeutics Inc (UNCY) fair value?
UNCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Unicycive Therapeutics Inc (UNCY) is between 15.56 to 33.28 according to relative valuation methord.
How does UNCY's valuation metrics compare to the industry average?
The average P/S ratio for UNCY's competitors is 11.71, providing a benchmark for relative valuation. Unicycive Therapeutics Inc Corp (UNCY) exhibits a P/S ratio of 1.12, which is -90.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Unicycive Therapeutics Inc (UNCY) as of Jan 10 2026?
As of Jan 10 2026, Unicycive Therapeutics Inc (UNCY) has a P/B ratio of 3.23. This indicates that the market values UNCY at 3.23 times its book value.
What is the current FCF Yield for Unicycive Therapeutics Inc (UNCY) as of Jan 10 2026?
As of Jan 10 2026, Unicycive Therapeutics Inc (UNCY) has a FCF Yield of -23.97%. This means that for every dollar of Unicycive Therapeutics Inc’s market capitalization, the company generates -23.97 cents in free cash flow.
What is the current Forward P/E ratio for Unicycive Therapeutics Inc (UNCY) as of Jan 10 2026?
As of Jan 10 2026, Unicycive Therapeutics Inc (UNCY) has a Forward P/E ratio of 1.59. This means the market is willing to pay $1.59 for every dollar of Unicycive Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Unicycive Therapeutics Inc (UNCY) as of Jan 10 2026?
As of Jan 10 2026, Unicycive Therapeutics Inc (UNCY) has a Forward P/S ratio of 1.12. This means the market is valuing UNCY at $1.12 for every dollar of expected revenue over the next 12 months.